What Happened? The President signed two companion Executive Orders (EO) on May 5, 2025 that collectively signal a significant federal pivot toward (i) accelerating the domestic manufacture of pharmaceuticals deemed “critical” to the national interest and (ii) tightening the biosafety and biosecurity framework that governs academic, industrial, and government-sponsored life-science research. The first EO – Regulatory Relief To Promote Domestic Production of Critical Medicines – directs the U.S….
By: Baker Donelson
By: Baker Donelson
